Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Stage IV NSCLC
- Interventions
- Drug: Kanglaite Injection
- Registration Number
- NCT01640730
- Lead Sponsor
- KangLaiTe USA
- Brief Summary
This study is for patients with advanced non small cell lung cancer that has progressed despite standard of care. The purpose of the study is to see if Kanglaite injection has any effect on survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
- confirmed (within last 3 months)progressive Stage IV NSCLC
- estimated life span of 3 months
- phase angle of at least 5 as measured by bioimpedance
Exclusion Criteria
- currently taking a lipid lowering medications
- has an imminently life threatening condition
- has pre-existing liver disease
- known allergy to soybeans
- uncontrolled diabetes or uncontrolled disturbance of lipid metabolism
- pregnant or lactating
- has a pacemaker or other implantable electronic medical device
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Kanglaite injection Kanglaite Injection -
- Primary Outcome Measures
Name Time Method Overall Survival from date of enrollment until date of death from any cause assessed up to 12 months
- Secondary Outcome Measures
Name Time Method Bioimpedance Phase Angle measured each month up to one year Palliation Response Measure each month up to one year quality of life survey and performance status
Trial Locations
- Locations (1)
The West Clinic
🇺🇸Memphis, Tennessee, United States